Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
Elajami TK, Alfaddagh A, Lakshminarayan D, Soliman M, Chandnani M, Welty FK
Journal of the American Heart Association · 41 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Posiblemente financiado por la industria
Según la declaración de financiación del texto completo.
Publicación
- Publicado
- 2017-07-01 · J Am Heart Assoc · vol. 6 · número 7
- Editorial
- Wiley
- Citado
- 51 citas · más que el 92% de estudios similares · 3.2× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 70 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY-NC-ND
- Áreas de investigación
- Fatty Acid Research and Health · Natural Products and Biological Research · Eicosanoids and Hypertension Pharmacology
- Palabras clave
- Medicine, Albuminuria, Internal medicine, Angiotensin receptor, Eicosapentaenoic acid, Diabetes mellitus, Endocrinology, Docosahexaenoic acid, Angiotensin-converting enzyme, Coronary artery disease, Type 2 Diabetes Mellitus, Creatinine, Angiotensin II, Blood pressure, Polyunsaturated fatty acid, Fatty acid
- MeSH
- humans, diabetic nephropathies, albuminuria, hypertension, diabetes mellitus, type 2, disease progression, docosahexaenoic acids, eicosapentaenoic acid, drug combinations, angiotensin ii type 1 receptor blockers, angiotensin-converting enzyme inhibitors, treatment outcome, risk factors, prospective studies, time factors, dietary supplements, adult, aged, aged, 80 and over, middle aged, boston, female, male, coronary artery disease
6 autores
- Tarec K. Elajami🇺🇸Beth Israel Deaconess Medical Center; Harvard University
- Abdulhamied Alfaddagh🇺🇸Beth Israel Deaconess Medical Center; Harvard University
- Dharshan Lakshminarayan🇺🇸Beth Israel Deaconess Medical Center; Harvard University
- Michael Y. Soliman🇺🇸Beth Israel Deaconess Medical Center; Harvard University
- Madhuri Chandnani🇺🇸Beth Israel Deaconess Medical Center; Harvard University
- Francine K. Welty🇺🇸Beth Israel Deaconess Medical Center; Harvard University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Albuminuria is a marker of inflammation and an independent predictor of cardiovascular morbidity and mortality. The current study evaluated whether eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplementation attenuates progression of albuminuria in subjects with coronary artery disease.
Methods and results
Two-hundred sixty-two subjects with stable coronary artery disease were randomized to either Lovaza (1.86 g of EPA and 1.5 g of DHA daily) or no Lovaza (control) for 1 year. Percent change in urine albumin-to-creatinine ratio (ACR) was compared. Mean (SD) age was 63.3 (7.6) years; 17% were women and 30% had type 2 diabetes mellitus. In nondiabetic subjects, no change in urine ACR occurred in either the Lovaza or control groups. In contrast, ACR increased 72.3% (PPr=0.394, P=0.01).
Conclusions
EPA and DHA supplementation attenuated progression of albuminuria in subjects with type 2 diabetes mellitus and coronary artery disease, most of whom were on an angiotensin-converting enzyme-inhibitor or angiotensin-receptor blocker. Thus, EPA and DHA supplementation should be considered as additional therapy to an angiotensin-converting enzyme-inhibitor or angiotensin-receptor blocker in subjects with type 2 diabetes mellitus and coronary artery disease.
Clinical trial registration
URL: http://www.clinicaltrials.gov. Unique identifier: NCT01624727.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC-ND).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.